Skip to main content

Development and Validation of HPLC Methods for the Determination of CYP2D6 and CYP3A4 Activities

Notice

The full text article is available externally.

View from original source.

Employment of in vitro experimentation to measure the effect of new chemical entities on human cytochrome P450 (CYP) marker activities represents a convenient approach in studying drug metabolism and pharmacokinetics. In this study, simple and accurate high performance liquid chromatograhic (HPLC) methods were developed and validated for quantitative analysis of CYP2D6-mediated dextromethorphan O-demethylation and CYP3A4-mediated testosterone 6β-hydroxylation. Both the assays showed a good linearity in the substrate concentration range of 0.05 – 20.0 μM and 0.01 – 100.0 μM with limit of detection (LOD) of 0.01 μM and 0.001 μM for CYP2D6 and CYP3A4, respectively. The intra- and inter-day precisions were from 7.21% to 12.22% and 3.09% to 14.60% for CYP2D6; and from 4.77% to 9.19% and 3.65% to 11.84% for CYP3A4. Assay accuracy for CYP2D6 ranged from 85.3% to 104.9% over dextrorphan concentrations of 0.05-5.0 μM; and that of CYP3A4 was 105.1% to 109.6% at hydroxytestosterone concentrations of 0.01-50 μM. Enzyme kinetic parameters obtained (Km and Vmax) using the two assays were within reported ranges. Thus, the assays were able to serve as activity markers in the assessment of pharmacokinetic drug interaction and metabolism mediated by CYP2D6 and CYP3A4.

Keywords: CYP2D6; CYP3A4; Cytochrome P450; Dextromethorphan; HPLC; Validation; corticosterone; drug metabolism; drug-drug interactions; pharmacokinetics

Document Type: Research Article

Publication date: September 1, 2012

More about this publication?
  • Current Pharmaceutical Analysis publishes authoritative reviews, written by experts in the field on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Call for Papers
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content